Source	Number of Participants	Ester	Administration	Regimen	Dosage	Testosterone Levels (Mean)	(E2) Estradiol Levels (Mean)	Time of Blood Drow	Timepoint of Measurment	Hormone Suppresants	Baseline Testosterone Levels *(Not Evaluated if Suppressants were used)*	Gonadotropins
Choi 2022	64 Both 124 46	Testosterone Cyponiate Testosterone Enanthate	(IM) Intramascular (SubQ) Subcutanious	Weekly	100mg	536.4 ng/dL 552.8 ng/dL	46.6 pg/mL 33.1 pg/mL	Trough	12th Week	-	313.6 ng/dL 246.6 ng/dL	-
Bhasin 2005 (Bhasin 2001 + Older Men; Test. levels only for Older Group)	13 12 11	Testosterone Enanthate	(IM) Intramuscular	Weekly	25mg 50mg 125mg	176ng/dL (SD ± 34) 274ng/dL (SD ± 18) 852ng/dL (SD ± 111)	-	Trough	16th Week	Leuprolide 7.5mg	Suppressed	*(Delfia)* LH 0.1 IU/L
Kaminetsky 2015	15 14	Testosterone Enanthate	(SubQ) Subcutanious	Weekly	100mg 50mg	**C**avg/week 895.5ng/dL (SD ± 279.8) **C**min 568.3ng/dL (SD ± 196.4) **C**avg/week 422.4 ng/dL (SD ± 123.9) *Note:* Indogenous production isn't fully suppressed. **C**min 272.9 ng/dL (SD ± 54.7)	Mean **C**avg/week 48.3pg/mL (SD ± 20.5) NS (Adult/Late Teen Transgender Men are unable to Suppress Endogenous Production on this dose) NS (Presumably less than 25.6pg/mL if used with GnRHa)	Intensive Sampling	6th Week	-	201.5 ng/dL 214.64ng/dL	-
Cooper 1998	10	Testosterone Cypionate	(IM) Intramuscular	Weekly	100mg	680ng/dL (SD ± 30)	-	Trough	15th Week	-	656ng/dL (SD ± 45)	-
Bhasin 2001	12 8 11	Testosterone Enanthate	(IM) Intramascular	Weekly	25mg 50mg 125mg	253ng/dL (SD ± 66) 306ng/dL (SD ± 58) 570ng/dL (SD ± 75)	-	Trough	16th Week	Leuprolide 7.5mg	Suppressed	*(IRMA)* (LH 0.3-0.6 SD ±0.1-0.3)
Kaminetsky 2019	Between 150-137(NS on the exact timepoint)	Testosterone Enanthate	(SubQ) Subcutanious	Weekly	75mg	501.9ng/dL (SD ± 172.70)	NS (No untitrated levels reported)	Trough	6th Week	-	231.6 ng/dL (SD ± 94.77)	-
Bi 2018	10	Testosterone Cypionate	NS (Presumably IM)	Weekly	100mg	1000ng/dL ± 685ng/dL	-	Mid-Interval Trough	15th Week	-	644ng/dL	(Median; Stimulated) >90% LH Inhibition *(wide CI)*
Gittleman 2019	21 (PK Study) 131 (Safety Population)	Testosterone Enanthate	(SubQ) Subcutanious	Weekly	75mg	478.9 ng/dL (SD is small, reported only in figure) 450.0 ng/dL (SD ± 150.5)	± 50pg/mL == -	Trough	6th Week	-	214.9ng/dL (SD ± 102.43)	-
Amory 2001 (Based on Matsumoto) Matsumoto 1990 (Old Essay)	10 9 10	Testosterone Enanthate	(IM) Intramuscular	Weekly	25mg 50mg 100mg	(Unreliable due to lack of Suppression) ± 550ng/dL ± 780ng/dL **C**avg/week 718ng/dL (SD ± 40.4)	-	Trough Mid-Interval Intensive Sampling	6th Month	-	500ng/dL	*(Delfia)* (LH 0.07 IU/L ± 0.02, FSH 0.06 IU/L ± 0.02) NS *(Old Essay)*
Borst 2014	40	Testosterone Enanthate	(IM) Intramuscular	Weekly	125mg	724ng/dL (SD ± 178)	43.8ng/mL	Trough	Within 12th Months	-	245ng/dL (SD ± 73)	NS (Authors:"TE reduced LH to near-zero concentrations")
Bhasin 2012	54	Testosterone Enanthate	(IM) Intramuscular	Weekly	50mg 125mg	385ng/dL 822ng/dL	-	NS (Presumably Trough)	20th Week	Leuprolide 7.5mg	Suppressed	NS (Suppressed)
Lakshman 2010 (Based on Bhasin 2001 and 2005 population)	Younger Men: 11 8 11 Older Men: 12 12 11	Testosterone Enanthate	(IM) Intramuscular	Weekly	25mg 50mg 125mg 25mg 50mg 125mg	NS (See Bhasin 2001 tT levels) NS (See Bhasin 2005 tT levels)	± 17pg/mL ± 17pg/mL ± 21pg/mL ± 18pg/mL ± 21 pg/mL ± 43pg/mL	Trough	12th and 16th Weeks	Leuprolide 7.5mg	Suppressed	NS (Suppressed)
El-Khatib 2021	169 (70 Tested for E2)	Testosterone Cypionate	(IM) Intramuscular	Weekly	100mg	639.4ng/dL	39.3 pg/mL E2 >40 pg/mL - 8/48 (17%) Subjects	Day 4-5	6th Month	-	234.8ng/dL (SD ± 63.7)	-
Wu 1999	8 8 8	Testosterone Enanthate	(IM) Intramascular	Weekly	50mg 100mg	331.7ng/dL (SD ± 17.3) 637ng/dL (SD ± 83.6) 758.5ng/dL (SD ± 83.6)	-	Trough	Mean of 4-24th Weeks measures	Desogestrel (Oral 150-300ug)	Suppressed	*(Delfia)* (< 0.05 IU/L LH, FSH)
Tenover 1992 (Old Essay)	13	Testosterone Enanthate	(IM) Intramuscular	Weekly	100mg	568.2ng/dL (SD ± 20.2)	41.7pg/mL (SD ± 4.1)	Trough	Mean of Monthly measures (3 Months)	-	334.6ng/dL (SD ± 11.6)	*(RIA)* LH 1.39 ± 0.28, FSH 1.5 ± 0.1 IU/L
Huang 2013	(Surgically Postmenopausal Women): 12 13 13 11	Testosterone Enanthate	(IM) Intramuscular	Weekly	3-mg 6.25mg 12.5mg 25mg	78 ng/dL 102 ng/dL 128 ng/dL 210 ng/dL	-	Trough	24th Week	-	NS	-
Coviello 2004	7	Testosterone Enanthate	(IM) Intramuscular	Weekly	100mg	827.7ng/dL (SD ± 57.7)	-	Trough	6th Month	Levonorgestrel (Oral 62.5 or 31.25ug)	Suppressed	*(Delfia)* (LH IU/L 0.08 ±0.03 FSH 0.1 ±0.04)
Yates 1999 (Old Assay)	10	Testosterone Cypionate	(IM) Intramuscular	Weekly	100mg	± 625ng/dL	-	Trough	Aprox. Mean of Biweekly measures (28 Weeks)	-	-	-